[en] Cyclodextrins (CDs) are promising solubility enhancers for inhaled drug delivery. However, they have dose-dependent effects on the respiratory epithelium, which may have advantages for permeability enhancement but also gives rise to safety concerns. In this study, the methyl thiazol tetrazolium (MTT) assay was used to compare a new sparingly methylated β-CD, Kleptose® Crysmeβ (Crysmeb) with the more established CD derivatives hydroxypropyl-γ-cyclodextrin (HPγCD), randomly methylated β-cyclodextrin (Rameb) and hydroxypropyl-β-cyclodextrin (HPβCD). The βCD derivatives affected cell metabolism in A549 cells in a concentration dependent manner with LDso of 56, 31 and 11 mM obtained for HPβCD, Crysmeb and Rameb, respectively. Calu-3 cells were less susceptible to βCD with an LDso of 25 mM being obtained for Rameb only. Permeability increases in Calu-3 cell layers were observed with βCD derivatives and a concentration dependency shown. The mechanism of permeability enhancement and its reversibility was investigated. Rameb produced an irreversible loss of cell layer barrier function at ≥25 mM, but perturbations of epithelial integrity were moderate and reversible in the case of HPβCD and Crysmeb (25-50 mM). Given its high solubilisation capacity, the low toxicity and transient absorption promoting properties, this study identifies Crysmeb as a promising adjuvant in formulations for inhalation.
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
Belhadj Salem, L.; Université de Liège - ULiège > Département de pharmacie > Département de pharmacie
Bosquillon, C.; Université de Liège - ULiège > Département de pharmacie > Pharmacie galénique
Rau, J.L., The inhalation of drugs: advantages and problems (2005) Respir. Care, 50 (3), pp. 367-382
Byron, P.R., Drug delivery devices: issues in drug development (2004) Proc. Am. Thorac. Soc., 1 (4), pp. 321-328
Patton, J.S., Byron, P.R., Delivering drugs to the body through the lungs (2007) Nat. Rev. Drug Discov., 6 (1), pp. 67-74
Tronde, A., Norden, B., Marchner, H., Wendel, A.-K., Lennernas, H., Bengtsson, U.H., Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs (2003) J. Pharm. Sci., 92, pp. 1216-1233
Taylor, G., The absorption and metabolism of xenobiotics in the lung (1990) Adv. Drug. Deliv. Rev., 5, pp. 37-62
Chan, H.K., Dry powder aerosol delivery systems: current and future research directions (2006) J. Aerosol Med., 19 (1), pp. 21-27
Leach, C.L., Inhalation aspects of therapeutic aerosols (2007) Toxicol. Pathol., 35 (1), pp. 23-26
Chow, A.H.L., Tong, H.H.Y., Chattopadhyay, P., Shekunov, B.Y., Particle engineering for pulmonary drug delivery (2007) Pharm. Res., 24 (3), pp. 411-437
Brewster, M.E., Loftsson, T., Cyclodextrins as pharmaceutical solubilizers (2007) Adv. Drug Deliv. Rev., 59 (7), pp. 645-666
Challa, R., Ahuja, A., Ali, J., Khar, R.K., Cyclodextrins in drug delivery: an updated review (2005) AAPS PharmSciTech, 6 (2), pp. E329-E357
Evrard, B., Bertholet, P., Gueders, M., Flament, M.P., Piel, G., Delattre, L., Gayot, A., Cataldo, D., Cyclodextrins as a potential carrier in drug nebulization (2004) J. Control. Release, 96 (3), pp. 403-410
Tewes, F., Brillault, J., Couet, W., Olivier, J.C., Formulation of rifampicin-cyclodextrin complexes for lung nebulization (2008) J. Control. Release, 129 (2), pp. 93-99
Srichana, T., Suedee, R., Reanmongkol, W., Cyclodextrin as a potential drug carrier in salbutamol dry powder aerosols: the in-vitro deposition and toxicity studies of the complexes (2001) Respir. Med., 95 (6), pp. 513-519
Leite Pinto, J.M.C., Cabral Marques, H.M., Beclomethasone/cyclodextrin inclusion complex for dry powder inhalation (1999) S. T. P. Pharm. Sci., 9 (3), pp. 253-256
Matilainen, L., Jarvinen, K., Toropainen, T., Nasi, E., Auriola, S., Jarvinen, T., Jarho, P., In vitro evaluation of the effect of cyclodextrin complexation on pulmonary deposition of a peptide, cyclosporin A (2006) Int. J. Pharm., 318 (1-2), pp. 41-48
Hussain, A., Yang, T., Zaghloul, A.A., Ahsan, F., Pulmonary absorption of insulin mediated by tetradecyl-beta-maltoside and dimethyl-beta-cyclodextrin (2003) Pharm. Res., 20 (10), pp. 1551-1557
Aguiar, M.M., Rodrigues, J.M., Silva, C.A., Encapsulation of insulin-cyclodextrin complex in PLGA microspheres: a new approach for prolonged pulmonary insulin delivery (2004) J. Microencapsul., 21 (5), pp. 553-564
Matilainen, L., Toropainen, T., Vihola, H., Järvinen, T., Jarho, P., Järvinen, K., In vitro toxicity and permeation of cyclodextrins in Calu-3 cells (2008) J. Control. Release, 126 (1), pp. 10-16
Loftsson, T., Byskov Vogensen, S., Brewster, M.E., Konrasdottir, F., Effects of cyclodextrin on drug delivery through biological membranes (2007) J. Pharm. Sci., 96, pp. 2532-2546
Grainger, C.I., Greenwell, L.L., Lockley, D.J., Martin, G.P., Forbes, B., Culture of Calu-3 cells at the air interface provides a representative model of the airway epithelial barrier (2006) Pharm. Res., 23 (7), pp. 1482-1490
Forbes, B., Human airway epithelial cell lines for in vitro drug transport and metabolism studies (2000) Pharm. Sci. Technol. Today, 3 (1), pp. 18-27
Foster, K.A., Oster, C.G., Mayer, M.M., Avery, M.L., Audus, K.L., Characterization of the A549 cell line as a type II pulmonary epithelial cell model for drug metabolism (1998) Exp. Cell Res., 243 (2), pp. 359-366
Pezron, I., Mitra, R., Pal, D., Mitra, A.K., Insulin aggregation and asymmetric transport across human bronchial epithelial cell monolayers (Calu-3) (2002) J. Pharm. Sci., 91 (4), pp. 1135-1146
Forbes, B., Ehrhardt, C., Human respiratory epithelial cell culture for drug delivery applications (2005) Eur. J. Pharm. Biopharm., 60 (2), pp. 193-205
Piel, G., Piette, M., Barillaro, V., Castagne, D., Evrard, B., Delattre, L., Study of the relationship between lipid binding properties of cyclodextrins and their effect on the integrity of liposomes (2007) Int. J. Pharm., 338 (1-2), pp. 35-42
Williams III, R.O., Mahaguna, V., Sriwongjanya, M., Characterization of an inclusion complex of cholesterol and hydroxypropyl-beta-cyclodextrin (1998) Eur. J. Pharm. Biopharm., 46 (3), pp. 355-360
Piel, G., Piette, M., Barillaro, V., Castagne, D., Evrard, B., Delattre, L., Betamethasone-in-cyclodextrin-in-liposome: the effect of cyclodextrins on encapsulation efficiency and release kinetics (2006) Int. J. Pharm., 312 (1-2), pp. 75-82
Mitic, L.L., Anderson, J.M., Molecular architecture of tight junctions (1998) Annu. Rev. Physiol., 60, pp. 121-142
Schneeberger, E.E., Lynch, R.D., The tight junction: a multifunctional complex (2004) Am. J. Physiol. Cell Physiol., 286 (6), pp. C1213-C1228
Tsukita, S., Furuse, M., Itoh, M., Multifunctional strands in tight junctions (2001) Nat. Rev. Mol. Cell Biol., 2 (4), pp. 285-293
Delie, F., Rubas, W., A human colonic cell line sharing similarities with enterocytes as a model to examine oral absorption: advantages and limitations of the Caco-2 model (1997) Crit. Rev. Ther. Drug Carrier Syst., 14 (3), pp. 221-286
Francis, S.A., Kelly, J.M., McCormack, J., Rogers, R.A., Lai, J., Schneeberger, E.E., Lynch, R.D., Rapid reduction of MDCK cell cholesterol by methyl-beta-cyclodextrin alters steady state transepithelial electrical resistance (1999) Eur. J. Cell Biol., 78 (7), pp. 473-484
Lambert, D., O'Neill, C.A., Padfield, P.J., Depletion of Caco-2 cell cholesterol disrupts barrier function by altering the detergent solubility and distribution of specific tight-junction proteins (2005) Biochem. J., 387 (PART 2), pp. 553-560
Smith, J., Wood, E., Dornish, M., Effect of chitosan on epithelial cell tight junctions (2004) Pharm. Res., 21 (1), pp. 43-49
Fuller, E., Duckham, C., Wood, E., Disruption of epithelial tight junctions by yeast enhances the paracellular delivery of a model protein (2007) Pharm. Res., 24 (1), pp. 37-47